BASEL (dpa-AFX) - Novartis (NVS) said that the U.S. Food and Drug Administration approved Lutathera for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Gastroenteropancreatic neuroendocrine tumors are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease.
Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, and in Japan for somatostatin receptor-positive neuroendocrine tumors.
Novartis said it is investigating a portfolio of radioligand therapies to treat a broad range of cancers, including Gastroenteropancreatic neuroendocrine tumors, lung, prostate, breast, colon, brain and pancreatic cancers.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
